Bicara Therapeutics Inc. (BCAX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.
Bicara Therapeutics Q2 Earnings Call Highlights
Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
CEO Claire Mazumdar sold 15,000 shares for a transaction value of approximately ~$301,000, based on a weighted average price of around $20.04 per share on May 18, 2026. This represented 3.98% of Mazumdar's direct holdings prior to the transaction, with post-transaction direct ownership at 362,152 shares.
Bicara Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 30 | $597 | $825.3 | $228.3 | 38.24% |
| NA Nizar Araji National Bank Of Canada /FI/ | 11 | $326.59 | $308.66 | -$17.93 | -5.49% |
| BG Bart Gancher Intech Investment Management LLC | 8,767 | $260,292.23 | $246,002.01 | -$14,290.22 | -5.49% |
| NM Nir Messafi Deep Track Capita LLP | 4.1M | $78.3M | $99.55M | $21.25M | 27.14% |
 Joseph Castro Nuveen LLC | 97,223 | $2.12M | $2.7M | $579,524.82 | 27.38% |
Bicara Therapeutics Inc. (BCAX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Bicara Therapeutics Inc. ever had a stock split?
Bicara Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Claire Mazumdar Clemon CEO | NASDAQ (NMS) Exchange | 055477103 CUSIP |
| US Country | 103 Employees | - Last Dividend | - Last Split | 13 Sep 2024 IPO Date |
Overview
Bicara Therapeutics Inc. is a dynamic player in the biopharmaceutical industry, focusing on the development of breakthrough bifunctional therapies aimed at treating solid tumors. Established in 2018 and operating from its Boston, Massachusetts base, Bicara stands out as a subsidiary of Biocon Limited, leveraging extensive resources and expertise to advance its clinical programs. The company's innovative approach to cancer treatment involves creating therapies that can simultaneously target multiple pathways, a methodology designed to offer a more comprehensive treatment modality for patients with solid tumors.
Products and Services
- Ficerafusp Alfa - This leading-edge bifunctional antibody represents the forefront of Bicara Therapeutics' product pipeline. It ingeniously marries an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that latches onto human transforming growth factor beta (TGF-b). This dual-action mechanism is meticulously designed to target and mitigate the progression of solid tumors. By focusing on both the EGFR pathway, known for its role in tumor growth and progression, and the TGF-b pathway, associated with cancer cell camouflage and immune system suppression, ficerafusp alfa embodies a holistic approach to solid tumor therapy.
